Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer
The researchers show that disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
Read MoreThe researchers show that disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
Read MoreThe researchers’ next steps include studying how DAPK3 promotes TNBC migration and assess its potential value as a therapeutic target.
Read MoreA new blood biomarker discovered in triple negative breast cancer patients could potentially indicate response to treatment.
Read MoreTargeting eIF4A to interfere with the synthesis of proteins the cancer needs to grow is producing promising results.
Read MoreThis study has advanced our understanding of the molecular mechanisms underlying the tumor-promoting activity of MAPK4.
Read MoreResearchers identified a tumor protein signature that predicts chemotherapy sensitivity and favorable clinical outcomes.
Read MoreThe findings help predict tumor response so that only effective treatments are given.
Read MoreResearchers identified a combination therapy for triple-negative breast cancer that results in durable tumor regression in an animal model.
Read MoreMAPK4 seems to be involved in promoting triple-negative breast cancer growth and its resistance to certain therapies.
Read MoreEndogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct as if fighting an infection.
Read More